Cargando…

Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials

BACKGROUND: Lebrikizumab is a monoclonal antibody that binds with high affinity to interleukin (IL)-13, thereby blocking the downstream effects of IL-13 with high potency. OBJECTIVES: To report integrated safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stein Gold, Linda, Thaçi, Diamant, Thyssen, Jacob P., Gooderham, Melinda, Laquer, Vivian, Moore, Angela, Natalie, Chitra R., Zhao, Fangyi, Meskimen, Eric, Elmaraghy, Hany, Montmayeur, Sonia, Gallo, Gaia, Jimenez, Gemma, de Bruin-Weller, Marjolein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191071/ https://www.ncbi.nlm.nih.gov/pubmed/37195407 http://dx.doi.org/10.1007/s40257-023-00792-6

Ejemplares similares

Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere)
por: Simpson, Eric L., et al.
Publicado: (2023)

Therapeutic Potential of Lebrikizumab in the Treatment of Atopic Dermatitis
por: Loh, Tiffany Y, et al.
Publicado: (2020)

Managing Atopic Dermatitis with Lebrikizumab – The Evidence to Date
por: Labib, Angelina, et al.
Publicado: (2022)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
por: Paller, Amy S., et al.
Publicado: (2023)

Targeting Interleukin 13 for the Treatment of Atopic Dermatitis
por: Lytvyn, Yuliya, et al.
Publicado: (2023)

The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Bashrahil, Bader, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Yosipovitch, Gil, et al.
Publicado: (2021)

New Developments in Biomarkers for Atopic Dermatitis
por: Thijs, Judith L., et al.
Publicado: (2015)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis
por: Eshtiaghi, Panteha, et al.
Publicado: (2018)

Lebrikizumab in the personalized management of asthma
por: Thomson, Neil C, et al.
Publicado: (2012)

Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis
por: ACHTEN, Roselie, et al.
Publicado: (2023)

The Treat-to-Target Project in Atopic Dermatitis: One Year On
por: DE BRUIN-WELLER, Marjolein, et al.
Publicado: (2023)

Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective
por: de Bruin-Weller, Marjolein, et al.
Publicado: (2021)

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2020)

Laboratory Safety of Dupilumab in Patients Aged 6–11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial
por: Paller, Amy S., et al.
Publicado: (2021)

Case report: Optical coherence tomography for monitoring biologic therapy in psoriasis and atopic dermatitis
por: Ha-Wissel, Linh, et al.
Publicado: (2022)

Food allergen sensitization pattern in adults in relation to severity of atopic dermatitis
por: Röckmann, Heike, et al.
Publicado: (2014)

Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study
por: Oosterhaven, Jart A.F., et al.
Publicado: (2019)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Real-World Treatment Patterns and Treatment Benefits among Adult Patients with Atopic Dermatitis: Results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey
por: AUGUSTIN, Matthias, et al.
Publicado: (2022)

Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year
por: Blauvelt, Andrew, et al.
Publicado: (2022)

Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial
por: Guttman-Yassky, Emma, et al.
Publicado: (2020)

Profile of lebrikizumab and its potential in the treatment of asthma
por: Maselli, Diego Jose, et al.
Publicado: (2015)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16
por: Thyssen, Jacob P., et al.
Publicado: (2023)

Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study
por: van Os-Medendorp, Harmieke, et al.
Publicado: (2015)

Usage and Users of Online Self-Management Programs for Adult Patients With Atopic Dermatitis and Food Allergy: An Explorative Study
por: van Os-Medendorp, Harmieke, et al.
Publicado: (2015)

Practical Management of Patients with Atopic Dermatitis on Dupilumab
por: Papp, Kim A., et al.
Publicado: (2021)

Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study
por: Thaçi, Diamant, et al.
Publicado: (2022)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Expert Perspectives on Key Parameters that Impact Interpretation of Randomized Clinical Trials in Moderate-to-Severe Atopic Dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab
por: Okragly, Angela J., et al.
Publicado: (2023)

Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis
por: Augustin, Matthias, et al.
Publicado: (2023)

Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
por: Bakker, Daphne S., et al.
Publicado: (2019)

Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement
por: Drucker, A.M., et al.
Publicado: (2018)

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs
por: Zuberbier, Torsten, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jd4l1q6ogg5qs392h3h9o73ja6